Time Until Partial Response in Metastatic Adrenocortical Carcinoma Long-Term Survivors
Éric Baudin(Institut Gustave Roussy), Vanina Bongard(Inserm), Jérôme Bertherat(Centre National de la Recherche Scientifique), Delphine Vezzosi(Université Toulouse III - Paul Sabatier), S. Hescot(Institut Curie), D. Drui(Centre Hospitalier Universitaire de Nantes), A. Berdelou(Université Paris-Sud), Bodale Djobo(Institut Gustave Roussy), Martin Schlumberger(Institut Gustave Roussy), F. Illouz(Signalisation Fonctionnelle des Canaux Ioniques et Récepteurs), Rossella Libé(Hôpital Cochin), Christine Do Cao(Centre Hospitalier Universitaire de Lille), Antoine Tabarin(Université de Bordeaux), Françoise Borson‐Chazot(Hospices Civils de Lyon), Christelle de la Fouchardière(Aix-Marseille Université), Claire Briet(Centre Hospitalier Universitaire d'Angers), Sophie Leboulleux(Geneva College), Philippe Caron(Hôpital Larrey), Magali Haissaguerre(Inserm)
Cited by 21
Related Papers
Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors
|European Journal of Endocrinology|2016|1.5k
Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial
|The Lancet Oncology|2021|1.3k
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
|Journal of Clinical Oncology|2020|1.2k
Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper
|Annals of Oncology|2015|897